Aim. To analyze and summarize the existing scientific approaches and mechanisms for innovation management when developing and registering medicines for the treatment of coronavirus disease (COVID-19) based on the implementation of a logistic approach and the creation of the integrated logistics innovation and information system.Materials and methods. Databases of the Internet, such as PubMed, the Food and Drug Administration, the European Medicines Agency were used. The retrospective, logical, and graphical methods of research, as well as the content analysis were applied. Results. In order to overcome the current therapeutic crisis in the world, 2 strategies are used: repurposing of the existing drugs (favipiravir, tocilizumab, etc.) and development of candidates for drugs with a direct targeted mechanism of action against COVID-19 (remdesivir, vaccines, etc.). Traditional approaches to the innovative process of activity as a closed one, oriented to the internal environment of the innovation system become ineffective. For this purpose, it is promising to apply a logistic approach to innovation management in the development and registration of medicines for the treatment of coronavirus disease (COVID-19). In the conditions of open innovation processes, those organizations and countries that can quickly implement an innovative idea gain a competitive advantage. It is necessary to manage innovation processes so that when an innovative idea enters the first stage, the idea is transformed into the final product with the shortest possible time. Logistization of innovation activities involves continuous improvement and optimization of the existing processes, allows you to organize innovation processes as a through integrated flow, reduce the time and costs for the implementation of innovative projects, gain benefits by optimizing innovative information, material and other flows.Conclusions. The result of the logistics of innovation in pharmacy will be: the creation of a complete cycle – from scientific research in scientific institutions, universities, pharmaceutical companies to the development of the production of innovative drugs; optimizing the use of resources associated with the implementation of innovative projects, as well as reducing the duration of the implementation of these projects; creation of a modern innovative infrastructure in the industry; wider attraction of investments in R&D from extra-budgetary sources; use of R&D results in training specialists.
Read full abstract